Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Sevinc, Alper; ÖZKAN, METİN; Ozet, Ahmet; DANE, FAYSAL; Oksuzoglu, Berna; Isikdogan, Abdurrahman; ÖZDEMİR, FEYYAZ; Uncu, Dogan; GÜMÜŞ, MAHMUT; EVRENSEL, TÜRKKAN; YAREN, ARZU; Kara, Oguz; TEKİN, Salim

doi:10.2147/ott.s106342

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia

Copy For Citation

Sevinc A., ÖZKAN M., Ozet A., DANE F., Oksuzoglu B., Isikdogan A., ...More

ONCOTARGETS AND THERAPY, vol.11, pp.419-426, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 11
Publication Date: 2018
Doi Number: 10.2147/ott.s106342
Journal Name: ONCOTARGETS AND THERAPY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.419-426
Keywords: chemotherapy, febrile neutropenia, neutrophil, ANC recovery, supportive care, myelosuppressive, COLONY-STIMULATING FACTOR, NON-HODGKINS-LYMPHOMA, FEBRILE NEUTROPENIA, G-CSF, RECEIVING CHEMOTHERAPY, CANCER-CHEMOTHERAPY, BREAST-CANCER, LUNG-CANCER, RISK, CHOP
Bursa Uludag University Affiliated: Yes

Abstract

Background: We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia.